Cargo Therapeutics, Inc. (CRGX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
After Plunging -69.58% in 4 Weeks, Here's Why the Trend Might Reverse for CARGO Therapeutics, Inc. (CRGX)
CARGO Therapeutics, Inc. (CRGX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why CARGO Therapeutics, Inc. (CRGX) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for CARGO Therapeutics, Inc. (CRGX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
CARGO Therapeutics, Inc. (CRGX) Upgraded to Buy: What Does It Mean for the Stock?
CARGO Therapeutics, Inc. (CRGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cargo Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Anup Radhakrishnan CEO | NASDAQ (NGS) Exchange | 14179K101 CUSIP |
| US Country | 167 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
CARGO Therapeutics, Inc. is a trailblazing clinical-stage biotechnology firm dedicated to advancing novel chimeric antigen receptor (CAR) T-cell therapies for cancer patients. Originally established as Syncopation Life Sciences, Inc., the company underwent a rebranding in September 2022, adopting the name CARGO Therapeutics, Inc. to reflect its focused mission. Founded in 2019, CARGO Therapeutics has quickly positioned itself in the forefront of CAR T-cell therapy innovation, operating from its headquarters in San Mateo, California. Its commitment to addressing the challenges of cancer treatment through cutting-edge cellular immunotherapies showcases its pioneering spirit in the biotechnological arena.
Products and Services
CRG-022: CRG-022 stands as CARGO Therapeutics, Inc.'s premier product candidate, marking a significant stride in the field of CAR T-cell therapy. This autologous CD22 CAR T-cell product is meticulously designed to combat the mechanisms underlying resistance in cancer therapy. By targeting CD22, an alternate tumor antigen prevalent in B-cell malignancies, CRG-022 distinguishes itself as a promising therapeutic option that seeks to improve outcomes for patients facing these challenging cancers.
CRG-023: Advancing its innovative portfolio, CARGO Therapeutics, Inc. also dedicates resources to the development of CRG-023, a tri-specific CAR T product candidate. This ambitious therapeutic approach ingeniously targets tumor cells by recognizing three B-cell antigen targets simultaneously. The pioneering nature of CRG-023 exemplifies the company’s commitment to pushing the boundaries of CAR T-cell therapy, aiming to provide a more comprehensive and potentially more effective treatment solution for cancer patients.
Contact Information
